Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
KITLG
REST API REST API
Homo sapiens
KITLG is differentially expressed in 271 experiments: 105 organism parts: lung, bone marrow, ... (103 more);, 185 disease states: normal, cervical carcinoma, ... (183 more);, 90 cell types 380 cell lines 30 compound treatments and 76 other conditions.
Synonyms SCF, Kitl, MGF, SF, KL-1, FPH2
Orthologs SCF_CHICK (Gallus gallus)   Kitl (Mus musculus)   SCF_BOVIN (Bos taurus)   Kitlg (Rattus norvegicus)   kitlg (Xenopus laevis)   SCF_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, protein binding, cytoskeleton, cytoplasm, cell proliferation, extracellular space, positive regulation of cell proliferation, membrane, negative regulation of apoptosis, growth factor activity, male gonad development, extracellular region, positive regulation of MAP kinase activity, cytokine activity, cell adhesion, hemopoiesis, germ cell programmed cell death, positive regulation of DNA replication, integral to membrane, signal transduction, positive regulation of Ras protein signal transduction, positive regulation of myeloid leukocyte differentiation, positive regulation of peptidyl-tyrosine phosphorylation, stem cell factor receptor binding, positive regulation of mast cell proliferation, ovarian follicle development, neural crest cell migration, negative regulation of mast cell apoptosis, positive regulation of melanocyte differentiation
InterPro Term SCF
UniProt Accession P21583, Q16493
Gene-Disease Assocation SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 7; SHEP7, HYPERPIGMENTATION, FAMILIAL PROGRESSIVE, 2; FPH2
Search EB-eye ENSG00000049130
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-22541, E-GEOD-6573, E-GEOD-1577, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (36 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-3529, E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
SW480
4
E-GEOD-18005, E-MEXP-1014, E-MTAB-37, E-GEOD-2509
LNCaP
2
E-GEOD-14464, E-GEOD-14990
A549
2
E-GEOD-6013, E-GEOD-3202
AGS
2
E-MTAB-37, E-GEOD-15460
HL-60
1
2
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
374 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, ... (41 experiments)

Factor Value U/D Experiments
CD71+ early erythroid
2
2
E-TABM-145, E-AFMX-5
macrophage
2
E-GEOD-5099, E-GEOD-22373
partially reprogrammed human induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
fibroblast
1
2
E-GEOD-3204, E-GEOD-3920, E-GEOD-26672
CD8+ T cell
1
E-GEOD-6740
cancer cell culture
1
E-GEOD-14990
84 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-MEXP-1121, ... (54 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-2514
cervical carcinoma
1
3
E-MEXP-1331, E-GEOD-5823, E-MTAB-37, E-MTAB-62
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
adrenocortical carcinoma
2
E-GEOD-10927, E-TABM-311
chronic lymphocytic leukemia
2
E-MTAB-37, E-GEOD-2466
control
2
E-GEOD-21912, E-GEOD-16363
179 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-697, E-TABM-782, E-TABM-868, E-GEOD-5099, ... (19 experiments)

Factor Value U/D Experiments
none
1
7
E-GEOD-412, E-TABM-782, E-TABM-868, E-MEXP-1958, E-GEOD-20719, ... (8 experiments)
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
valproic acid
1
E-GEOD-1615
unknown
1
E-GEOD-7307
Cxcl12
1
1
E-GEOD-7307
cigarette smoke
1
E-TABM-127
24 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-21374, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-GEOD-3891, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-GEOD-2509, E-TABM-147, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-GEOD-17476, E-GEOD-2466, E-TABM-868, E-GEOD-18005, E-TABM-601, ... (16 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-TABM-127, E-GEOD-20504, E-MEXP-1446, E-GEOD-9764, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-GEOD-10433, ... (27 experiments)

Infection
studied in E-GEOD-2405, E-MEXP-561, E-GEOD-17400, E-GEOD-6802

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Library source
studied in E-GEOD-19323

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-GEOD-2487

Population
studied in E-GEOD-4922, E-GEOD-4342

Pr ihc
studied in E-GEOD-21653

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-19445, E-GEOD-19246

pt
studied in E-GEOD-21653

Qrt pcr areg dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-1315, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7540, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541, E-GEOD-4922

Tumor size
studied in E-GEOD-6532

Processing time: 0.436 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM